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Abstract: The purpose of this study is to develop a smartphone-based self-care program (Hep B
Care®) for patients with the chronic hepatitis B virus (HBV). To pilot test the feasibility of Hep B
Care®, 63 participants with chronic HBV were recruited from an outpatient clinic at S hospital, Seoul,
South Korea (experimental group [EG]: n = 30, control group [CG]: n = 33) between February and
July 2016. Hep B Care® was developed based on the theory of self-care whilst having a chronic
illness. During the 12-week intervention period, the application: (1) provided information about
the disease, medication, nutrition, and exercise; (2) encouraged taking medication and exercise
using alarms; and (3) enabled the exchange of messages between healthcare providers and patients.
Salivary cortisol, fatigue, depression, anxiety, knowledge of the HBV, quality of life, and medication
adherence were all measured as outcomes. Cortisol levels were significantly increased, knowledge of
the HBV was improved, and the mean anxiety score was significantly decreased in the EG. Thus, Hep
B Care ® partially improved health outcomes in the EG. We recommend that large trials be conducted
among patients with the HBV. The smartphone-based self-care program for providing education and
coaching is effective for improving knowledge and reducing anxiety among patients with the HBV.
Keywords: hepatitis B surface antigens; chronic disease; self-care; mobile applications; quality of life
1. Introduction
Hepatitis B is caused by a viral infection. In many cases, patients with the HBV are
asymptomatic but, in some cases, they may present symptoms that include jaundice, dark
urine, extreme fatigue, nausea, and vomiting. Various symptoms, including acute liver
failure or even death, may also occur. The long-term complications of the HBV include liver
diseases, such as cirrhosis and hepatocellular carcinoma [1,2]. According to the statistics
provided by World Health Organization (WHO), deaths from hepatitis B virus (HBV) in
2015 numbered 887,000 worldwide, most of which were due to cirrhosis and hepatocellular
carcinoma [1]. In South Korea, 3.8% of the total population (4.2% males and 3.4% females)
is still infected with the HBV [3,4] and approximately 70% of South Korean patients with
liver cirrhosis and hepatocellular carcinoma have the HBV surface antigen (HBsAg) [2].
The management of the HBV should be accompanied by lifelong self-care to improve the
liver condition of patients and prevent a worsening of the disease [1,2]. However, previous
studies have reported that the level of self-care compliance among patients with the HBV
is low to moderate [5].
In previous studies, self-care interventions for patients with the HBV were provided
using a method of face-to-face group education [6,7]. However, this method is costly and
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has further disadvantages, such as a deviation of the effects, depending on the level of the
provider’s skill and the lack of participant confidentiality [8–10]. To address these problems,
digital applications (apps) on smart devices provide a new platform for interventions for
patients with chronic diseases. Such apps enhance the mutual communication between
patients and healthcare providers and are cost-effective [8,10,11]. In addition, the user is
able to access the app in real time [12,13]. However, studies on self-care interventions for
hepatitis B patients using apps are lacking. The present study differs from prior studies in
that we develop an app intervention based on the self-care theory. Therefore, this theory-
based study will increase the understanding of the health problems and circumstances of
patients with the HBV who need assistance with self-care [14]. In addition, the development
process in this study can provide useful information for healthcare providers who create
interventions that facilitate self-care for patients with the HBV using the app.
The aims of our study are to: (1) develop a theory-based self-care program using a
smartphone app and to (2) test the feasibility of the developed intervention.
2. Materials and Methods
This study was conducted in two phases: (1) developing a self-care program (Hep B
Care®, Seoul, Korea) using a mobile app for patients with the HBV and (2) pilot testing
Hep B Care® for feasibility.
2.1. Phase I: Development of a Self-Care Program
2.1.1. Theoretical Basis for Intervention
This app is based on the theory of self-care of patients with a chronic illness [15], which
was developed to capture a holistic view of how patients with chronic diseases are treated.
Self-care is defined as the process of a patient recognizing and responding to changes in
themselves after the acute phase of disease development. There are three key concepts
in this theory: self-care maintenance, self-care monitoring, and self-care management.
Self-care maintenance comprises the behaviors used by patients with a chronic illness to
maintain physical and emotional stability. Self-monitoring is the process through which
patients observe themselves to identify the changes in signs and symptoms of the disease.
Self-maintenance is defined as the patients’ behaviors for improving personal well-being,
preserving their health, or maintaining physical and emotional stability. Riegel et al. [15]
also suggest that healthcare professionals provide tailored interventions, including the
assurance each patient has easy access to providers/care within the organized healthcare
system. These definitions of patients, self-care, and the role of healthcare providers were
judged to be the most appropriate for the background and patient context of this study and
thus formed the basis of our intervention.
2.1.2. Literature Review for the Selection of Intervention Content
To develop this mobile app, the investigators reviewed the literature in the following
way: (a) databases: PubMed, CINAHL Plus with Full Text, EMBASE, KoreaMed, KISS,
and RISS; (b) search period: from 2004 to 2016; and (c) keywords: “Hepatitis” [MeSH] or
“Hepatitis, Chronic” [MeSH] or “Chronic hepatitis” and “Self Care” [MeSH] or “Self-care”
or “Self management” or “Self-management” or “Nonpharmacological intervention” or
“Intervention, Nonpharmacological” or “Nursing intervention” or “Intervention, Nursing”.
Through the literature review, we identified the status of the interventions using
mobile apps that were available at the time, selected content for the app, and decided on
how the app would deliver the content. The intervention content was determined based
on the operational definition of the concept in the self-care of chronic illness theory [15].
Detailed information about this theoretical framework is shown in Figure 1.
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2.1.3. Expert Content Review
The content of the app was reviewed by an expert group consisting of a physician,
two nurses, and two clinical dieticians in a liver clinic. Following the expert review, the
development team created a beta version of the mobile app. The beta version was tested
at the Department of Gastrointestinal Medicine, in the outpatient clinic at Y University
Medical Center, with 10 individuals (5 from the experimental group [EG] and 5 from the
control group [CG]), after which the final version was pilot tested.
2.2. Phase II: Self-Care Program Pilot Test
2.2.1. In ervention P otocol: EG Versus CG
Participants were ran omly assign d to either the EG or CG using the closed-
envelope m thod. The researcher printed 80 sheets of paper of the same material and size,
numbered EG #1 to #40 and CG #1 to #40. The paper was folded to the s me size, placed in
a white envelope of the same size, and sealed. A research assista t mixed the envelopes
and placed them in a box. Pati nts who agreed to participate in the study were asked to
choose one of the sealed envelopes.
The EG installed the self-management of the HBV program app on their mobile
phones. The researcher provided training on how to use it. This app provided information
regarding the disease process, medication, nutrition, and exercise, and used alarms to
encourage users to take medication and exercise. The EG received the knowledge test
results on the next day of study-enrollment and learned about the areas in which they
lacked knowledge. They also received messages encouraging them to use the app four
times during the study period.
The CG was provided with patient education materials and usual healthcare services.
Salivary cortisol concentrations were measured after waking up at each time point before
the intervention program and 12 weeks later, which was the endpoint of the program. In
addition, questionnaires assessing fatigue, quality of life (QOL), depression, and anxiety
were administered beforethe beginning of the intervention program and 12 weeks later.
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In the planning stage, we did not register the study in the WHO registry network be-
cause it was primarily a pilot test of the feasibility of Hep B Care®. However, the completed
study was registered according to the WHO’s definition of clinical trials (PRE20201213-002).
2.2.2. Setting and Sample
For this pilot process, the participants were 68 individuals (EG: n = 32, CG: n = 36) with
chronic HBV from an outpatient clinic in Yonsei University Medical Center, in Seoul, South
Korea. The eligibility criteria were patients with the HBV: (1) in whom HBsAg had been
detected at least six months earlier and the HBV had been diagnosed at least three months
earlier; (2) aged > 40 who had not developed liver cirrhosis or cancer; and (3) who had
taken an antiviral medication. The exclusion criteria were patients who: (1) were pregnant
or had any mental diseases and (2) had other infectious diseases and comorbidities. The
flow from enrollment to analysis is illustrated in Figure 2.
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Figure 2. Participant flow.
2.2.3. Outcome Measurements
The study outcomes were derived as follows through a literature review. Fatigue is
the most frequently reported physical symptom in patients with the HBV, and cortisol is a
representative biomarker associated with fatigue [16]. Anxiety and depression have also
been reported as the most prevalent emotional symptoms in patients with the HBV [17].
Knowledge of disease is the main factor in self-care [18]. Antiviral therapy for chronic HBV
is essential for treatment, and patient compliance is a critical factor in antiviral therapy [19].
QOL is widely recognized as an outcome demonstrating the effectiveness of treatment.
Cortisol was obtained from saliva samples drawn in the morning and before bed. The
quality control of cortisol ELISA showed intra- and inter-assay coefficients of variations of
6.3% and 10.4%, respectively. The recovery of added cortisol was 101%, and the sensitivity
of the assay was 0.071 ng/mL.
To assess knowledge, the investigators evaluated and revised the Level of HBV Knowl-
edge instrument originally developed by Yang (2012) [20]. The revised version consists of
26 items with five subscales: general characteristics of the HBV, infection process, infection
prevention, treatment, and management of lifestyle. Participants can answer yes or no, and
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one point is awarded for each correct answer. The range of the total score is 0–26 points,
which is converted to 0–100 points, to help patients to understand their level of knowledge.
A high score represents a high knowledge level. The reliability was KR-20 = 0.94 in the
original version [20] and KR-20 = 0.75 in this study.
The Korean version of the revised Piper Fatigue Scale was used to measure levels
of fatigue [21]. The Piper Fatigue Scale was originally developed in English [22]. The
instrument consists of 22 items and four subscales: behavioral/severity, affective meaning,
sensory, and cognitive/mood. The total score range is from 0 to 10; a high score represents
a high fatigue level. The reliability of the Korean version was α = 0.96 [21]. In this study,
the reliability was α = 0.96.
Depression was assessed using the Korean version of the Beck Depression Inven-
tory [23]. It contains 21 items, and the total score ranges from 0 to 63. A high score
represents a high level of depression. The reliability of the Korean version was α = 0.93 [23].
In this study, the reliability was α = 0.95.
Anxiety was measured using the Korean version of the Beck Anxiety Scale [24]. It is
composed of 21 items, and the score ranges from 0 to 63. A high score represents a high
anxiety level. The Korean version showed a reliability of α = 0.93 [25]. In this study, the
reliability was α = 0.94.
For QOL, we used the Korean version of the Hepatitis B Quality of Life (HBQOL)
questionnaire [26], which consists of 31 items with 6 subscales: psychological well-being,
anticipation anxiety, stigma, weakness, vitality, and vulnerability of general health. Each
uses a five-point Likert-type scale. The range of total scores is from 0 to 100; a high score
represents a high level of QOL. The reliability of the Korean version was α = 0.96 [26]. In
this study, the reliability was α = 0.97.
Medication adherence was measured using the Morisky Medication Adherence Scale.
This self-report scale was developed to measure the medication adherence in patients with
hypertension [27].
2.2.4. Data Collection
We collected data between February and October 2016. The participants’ pre-intervention
cortisol levels were measured twice (the evening before and the morning of the interven-
tion); they were also measured twice post-intervention (in the evening and the following
morning). Additionally, all participants completed questionnaires before the intervention
and again after 12 weeks.
2.2.5. Statistical Analyses
SPSS version 22.0 (IBM Corp., Armonk, NY, USA) was used for the analysis. De-
scriptive statistics were used to analyze the demographic and disease characteristics of
the participants. A chi-square test and an independent t-test were used to compare the
homogeneity of the two groups. We also performed paired t-tests and an ANCOVA to
assess the feasibility of this pilot study. The statistical significance level was set at p < 0.05.
2.2.6. Ethical Considerations
This study was approved by the Institutional Review Board of a university medical
center (IRB#4-2015-1039), and written informed consent was obtained from all participants.
Before the study began, the researcher directly explained to the participants the study pur-
pose and procedure; benefits and risks; privacy protection and confidentiality of research
data; voluntary nature of participation; and the option to withdraw. Furthermore, the
participants were provided with the researcher’s contact information. In the outpatient in-
terview room, which is an independent space, the researcher checked whether the purpose
and contents of the study were fully understood along with the explanations above.
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3. Results
3.1. Part I: Development of Hep B Care®
Content and Functions
In accordance with the literature and guidelines for managing the HBV, the program
consisted of a library section for disease information, exercise, diet, and medication; a
record section for daily exercise and taking medications; and a Q&A with the provider. We
listed self-care practices, including items that had been determined based on empirical
knowledge and the literature review concerning patients with the HBV. The self-practice
items were arranged according to the self-care of chronic illness theory concepts. For
example, self-care maintenance is defined as the “behaviors performed by patients with a
chronic illness to maintain physical and emotional stability”. [15] Therefore, the concept of
self-care maintenance was narrowed down to a “modification of lifestyle” and “managing
medication adherence”. These contents are delivered through the app’s library function,
which allows the patient to find the necessary information, and the alarm function, which
alerts them to when it is time to take the medication or engage in exercise.
The patient can search for the necessary information, and the library function collects
only the information necessary for the individual. In addition, the level of individual
knowledge about chronic HBV can be measured in the app, and the administrator can
be notified of the topic for which the patient needs further information. Also, self-care
monitoring is defined as the “process of observing oneself for changes in symptoms” [15].
We narrowed that definition down to “monitoring treatment adherence”, “monitoring lab
results”, and “monitoring fatigue level” for the purposes of the app. Alarms are set to
notify patients of their upcoming scheduled outpatient visits (alerts are provided one week
before and one day before the scheduled appointment dates) and if there are lab results
that show abnormal values, the patient is sent a notification via text.
In the self-care chronic illness theory, self-care management is defined as the “evalua-
tion of changes in physical and emotional symptoms to determine if action is needed” [15].
For use in the smartphone app, this concept was narrowed down to a “consultation
with/feedback from healthcare providers.” Participants could ask questions related to
self-care via text message and look up their history of self-management in any given week
or month.
The final version of the app was developed after modifying the beta version based on
participants’ experiences and feedback. In the final version, technical errors were rectified,
and the following content was added: brand and generic names of medications and foods
for high-protein diets (Figure 3). We named the program “Hep B Care®”.
3.2. Part II: Pilot Study of Feasibility of the Hep B Care® Program
Pilot study analyses revealed that there were no statistical differences in the baseline
characteristics between the EG and CG. The mean (standard deviation) age was 55.0 (7.35)
years in the EG and 52.3 (7.35) years in the CG. In each group, 21 patients (70% and 63.6%,
respectively) were male (Table 1).
3.2.1. Results by Measured Outcomes
Cortisol
EG participants’ cortisol levels were significantly increased at week 12 (p = 0.037)
compared to pre-intervention (Table 2). However, when pre-cortisol values were adjusted,
there was no significant difference between the groups (Table 3).
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Table 1. Demographic characteristics of participants in a pilot test of a smart app for HBV management. N = 63.
Characteristics
Experimental (n = 30) Control (n = 33)
Mean ± SD or n (%) χ2 or t p
Age, years 55.0 ± 7.35 52.3 ± 7.35 1.446 0.153
Sex Male 21 (70.0) 21 (63.6) 0.286 0.789Female 9 (30.0) 12 (36.4)
Marital status Married 27 (90.0) 32 (97.0) 1.284 0.340Single or widowed 3 (10.0) 1 (3.0)
Occupation Employed 15 (50.0) 22 (66.7) 1.801 0.208Unemployed 15 (50.0) 11 (33.3)
Education ≤High school 11 (36.7) 17 (51.5) 1.403 0.312>High school 19 (63.3) 16 (48.5)
Household income
(Month, KRW)
<2 million 4 (13.4) 3 (9.1)
3.507 0.676
2–3 million 3 (10.0) 6 (18.2)
3–4 million 5 (16.7) 3 (9.1)
4–5 million 7 (23.2) 8 (24.2)
5–6 million 11 (36.7) 13 (39.4)
Length of diagnosis (months) 90.8 ± 55.06 97.1 ± 84.69 −0.242 0.811
Hospitalization Yes 6 (20.0) 7 (21.2) 0.014 1.000No 24 (80.0) 26 (78.8)
Family history of
HBV
Yes 23 (76.7) 25 (75.8) 0.007 1.00No 7 (23.3) 8 (24.2)
Comorbidity Yes 7 (23.3) 10 (30.3) 0.387 0.581No 23 (76.7) 23 (69.7)
Taking antivirals Yes 30 (100.0) 33 (100.0)
Duration of taking antivirals (months) 88.6 ± 60.47 87.6 ± 48.90 0.069 0.945
HBV DNA
Target not detected 11 (36.7) 9 (27.3)
2.350 0.329<20 14 (46.7) 13 (39.4)
≥20 5 (16.6) 11 (33.3)
AST 27.3 ± 15.98 24.4 ± 9.07 0.908 0.367
ALT 24.2 ± 13.42 26.6 ± 21.9 −0.526 0.601
Comorbidity: hypertension, diabetes mellitus, hyperlipidemia, and atherosclerosis, etc.; App: application; ALT: alanine aminotransferase;
AST: aspartate aminotransferase; DNA: deoxyribonucleic acid; HBV: hepatitis B virus; KRW: Korean Won; and SD: standard deviation.
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Table 2. Comparison of outcomes of groups in a 12-week pilot test of a smart app intervention for HBV management. N = 63.
Variables
Experimental Group (n = 30) Control Group (n = 33)
Pre Post Pre Post
Mean ± SD t (p) Mean ± SD t (p)
Cortisol 1.90 ±0.44 2.02 ±0.44 −2.19 (0.037 *) 1.47 ±0.62 1.35 ±0.48 1.03 (0.313)
Knowledge Total 78.98 ±11.39 83.65 ±1.49 −2.81 (0.009 *) 74.92 ±13.66 77.39 ±16.11 −1.47 (0.152)
GE 89.29 ±24.09 94.05 ±13.00 −1.00 (0.326) 87.69 ±18.19 90.91 ±20.87 −1.21 (0.235)
TM 77.23 ±18.34 85.71 ±13.91 −2.75 (0.011 *) 74.62 ±19.13 77.27 ±21.30 −0.96 (0.344)
IP 72.62 ±19.88 75.00 ±15.38 −0.61 (0.547) 62.12 ±20.53 65.15 ±23.33 −0.97 (0.338)
TR 89.29 ±12.74 89.29 ±13.86 0 (1.000) 85.45 ±13.48 86.06 ±15.40 −0.20 (0.845)
DA 71.43 ±16.27 77.68 ±20.79 −1.57 (0.129) 71.97 ±19.52 75.00 ±22.53 −0.75 (0.458)
Fatigue 4.07 ±2.50 4.09 ±2.70 −0.11 (0.914) 3.83 ±2.21 3.68 ±2.00 0.78 (0.442)
Depression 10.23 ±10.75 9.73 ±10.66 0.44 (0.663) 8.36 ±8.82 7.18 ±6.78 1.08 (0.286)
Anxiety 30.27 ±10.04 27.90 ±9.01 2.17 (0.038 *) 29.24 ±8.70 27.15 ±4.96 1.67 (0.101)
HBQOL Total 63.31 ±22.60 65.43 ±22.05 −1.02 (0.317) 67.28 ±21.41 66.79 ±20.23 0.25 (0.807)
PW 76.94 ±25.38 77.69 ±25.05 −0.25 (0.806) 78.79 ±24.29 79.71 ±23.69 −0.45 (0.658)
AA 43.06 ±24.01 48.06 ±28.34 −1.85 (0.075) 48.23 ±25.79 44.57 ±26.32 0.98 (0.333)
ST 65.00 ±28.42 65.42 ±26.74 −0.16 (0.874) 69.82 ±22.54 70.58 ±23.01 −0.29 (0.771)
WN 78.89 ±25.31 78.89 ±24.64 0 (1.000) 80.30 ±25.41 84.60 ±20.21 −1.18 (0.248)
VI 64.58 ±26.48 70.00 ±29.43 −1.58 (0.125) 68.18 ±24.67 66.86 ±22.34 0.46 (0.652)
VU 42.22 ±24.07 43.89 ±26.98 −0.46 (0.651) 51.52 ±29.86 46.97 ±27.31 0.92 (0.363)
Medication adherence 1.20 ± 1.10 1.17 ±1.05 0.25 (0.801) 1.52 ±1.12 1.24 ±1.03 1.39 (0.174)
* p < 0.05, App: application; HBV: hepatitis B virus; GE: general characteristics; TM: transmission; IP: infection process; TR: treatment; DA:
daily management of lifestyle; PW: psychological well-being; AA: anticipation anxiety; ST: stigmatization; WN: weakness; VI: vitality; and
VU: vulnerability.






(n = 33) F (p)
Pre-Post Pre-Post
LS Mean ± SE
Cortisol 1.85 ± 0.08 1.39 ± 0.07 1.68 (0.200)
Knowledge Total 0–100 82.68 ± 1.61 79.15 ± 1.47 9.15 (0.004 *)
GE 0–100 93.96 ± 2.68 91.50 ± 2.47 16.09 (<0.001 *)
TM 0–100 85.16 ± 2.67 78.20 ± 2.46 5.51 (0.022 *)
IP 0–100 73.52 ± 3.21 68.84 ± 2.92 6.59 (0.013 *)
TR 0–100 87.97 ± 2.60 86.58 ± 2.38 1.39 (0.243)
DA 0–100 77.82 ± 3.86 74.89 ± 3.55 0.008 (0.931)
Fatigue 0–10 3.98 ± 0.22 3.77 ± 0.21 0.43 (0.514)
Depression 0–63 8.93 ± 0.99 7.67 ± 0.95 0.49 (0.487)
Anxiety 0–63 27.51 ± 0.87 27.31 ± 0.83 8.18 (0.006 *)
HBQOL Total 0–100 67.20 ± 2.00 65.27 ± 1.91 0.01 (0.919)
PW 0–100 78.44 ± 2.50 78.96 ± 2.38 0.22 (0.640)
AA 0–100 50.78 ± 3.28 42.90 ± 3.12 0.57 (0.452)
ST 0–100 67.48 ± 2.56 68.73 ± 2.45 0.43 (0.836)
WN 0–100 79.42 ± 3.06 84.28 ± 2.92 2.80 (0.100)
VI 0–100 71.63 ± 3.09 65.69 ± 2.95 0.29 (0.594)
VU 0–100 47.70 ± 4.09 44.89 ± 3.86 1.13 (0.292)
Medication adherence 1–4 1.29 ± 0.15 1.18 ± 0.14 1.04 (0.312)
* p < 0.05, App: application; HBV: hepatitis B virus; SE: standard error; GE: general characteristics; TM: transmission; IP: infection
process; TR: treatment; DA: daily management of lifestyle; PW: psychological well-being; AA: anticipation anxiety; ST: stigmatization; WN:
weakness; VI: vitality; and VU: vulnerability.
Knowledge
EG participants’ knowledge levels were significantly increased at week 12 (p = 0.009)
compared to pre-intervention (Table 2). In the subdomains, the “knowledge of transmis-
sion” had significantly increased in the EG (p = 0.011) (Table 2). When the pre-knowledge
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values were adjusted, we found a significant difference between the EG post-intervention
scores and the CG scores (p = 0.004). Also the “knowledge of general characteristics”,
“knowledge of transmission”, “knowledge of infection process”, and “knowledge of treat-
ment” had significantly increased in the EG (Table 3).
Fatigue
There was no significant difference in pre- and post-fatigue between the two groups,
and fatigue did not affect the intervention’s effectiveness (Tables 2 and 3).
Depression
There was no significant difference in pre- and post-depression between the two
groups, and depression did not affect the intervention’s effectiveness (Tables 2 and 3).
Anxiety
EG participants’ anxiety levels were significantly increased at week 12 (p = 0.038)
compared to pre-intervention (Table 2). When the pre-anxiety values were adjusted, we
found a significant difference between the EG post-intervention scores and the CG scores
(p = 0.006) (Table 3).
Quality of Life (QOL)
There was no significant difference in pre- and post-QOL between the two groups,
and QOL did not affect the intervention’s effectiveness (Tables 2 and 3).
Medication Adherence
There was no significant difference in pre- and post-medication adherence between
the two groups, and the medication adherence did not affect the intervention’s effectiveness
(Tables 2 and 3).
4. Discussion
Patients with chronic HBV need to perform self-care throughout their lifetime. After
the treatment of acute symptoms, healthcare providers need to ensure that patients are
protected from worsening complications of the liver disease by encouraging them to engage
in infection prevention by taking regular medication, exercising, and performing dietary
management. In this study, we developed Hep B Care® as a self-care program using a
mobile app and pilot tested its feasibility. The Hep B Care® program has the following
three characteristics.
First, the component of knowledge about the HBV is highlighted. In previous studies,
healthcare providers educated participants about the HBV using traditional approaches,
such as seminars [28,29]. Conversely, Hep B Care® provides knowledge in a more inter-
active way. Specifically, participants can receive immediate feedback after assessing their
level of knowledge and review the material anytime; thus, this system can provide tailored
information and may improve participation in an intervention program. In studies target-
ing other diseases, such as cancer, or for the health promotion of the general population,
participants’ knowledge has been shown to increase more when an intervention includes
feedback, such as showing them a message that confirms their status [30,31].
Second, our program emphasizes interactive communication. Participants in the pilot
study could send messages with their questions to their healthcare providers whenever they
wanted. Previous studies have shown that the interaction between patients with diabetes
mellitus and the healthcare providers positively affected their self-care [32,33]. Given that
patient engagement is essential to improving patient outcomes [34], the interaction enabled
by Hep B Care® might increase the patients’ engagement in the intervention.
Third, the investigators sent encouraging messages to patients four times via this pro-
gram. Compliance is another factor known to influence the effectiveness of treatment [35],
and encouragement from the healthcare provider is known to have a major impact on
Int. J. Environ. Res. Public Health 2021, 18, 11139 10 of 13
adherence [36]. Hence, previous studies have also attempted to increase the participants’
compliance through encouraging messages [37,38].
Through the Hep B Care® program with the above characteristics, the following
three key findings were obtained in this pilot study. First, cortisol levels in the EG were
significantly increased after the intervention, compared to the cortisol levels before the
intervention. Although the Hep B Care® program had no significant effect on perceived
fatigue in the EG, their cortisol levels changed significantly. A previous study on Korean
patients with the HBV reported that patients with higher fatigue levels had lower levels
of cortisol [16]. This pattern of cortisol is similar to that of chronic fatigue syndrome [39].
To better assess the effects of the Hep B Care® program on fatigue as one of the major
symptoms in individuals with the HBV, further studies will need to be conducted with
objective outcome indicators using a wider range of biomarkers.
Second, the EG demonstrated a significant improvement in knowledge and a reduc-
tion in anxiety, despite the small change in the mean scores. The participants’ level of
knowledge in this study was relatively high, which is thought to be due to the long time
since being diagnosed with HBVand the high level of education. Enhancing the patients’
knowledge of these chronic diseases is necessary to ensure the intervention addresses any
shortcomings (rather than simply improving their overall scores). Meanwhile, patients
with chronic HBV have anxiety about infection and the deterioration of liver function, and
these forms of mental stress appear to negatively impact their QOL [40,41]. Although there
have been few intervention studies in patients with the HBV, randomized controlled trial
studies with patients with chronic illness have shown that educational interventions reduce
anxiety [42,43]. Since anxiety in these studies was assessed with a general instrument,
there might have been a limitation to explaining the disease-specific anxiety experienced
by patients with the HBV. Therefore, it is necessary to identify the characteristics of anxiety
in patients with the HBV in further research.
Third, HBQOL was not significantly different after the intervention in this study. It is
known that self-care intervention improves the health-related quality of life (HRQOL) in
patients with chronic diseases [44,45]. Self-care for managing physical symptoms can lead
to an improvement in HRQOL in patients with chronic illnesses [46]. However, the level of
fatigue as a major symptom was not significantly different in this study. This could be the
reason why the HBQOL was not significantly different after the intervention. Therefore,
the relationship between fatigue management and the HBQOL needs to be clarified in this
population.
Our findings show that this tailored intervention using a smartphone app for patients
with the HBV is feasible. There are few mobile interventions targeting this population, so
the current program may help to improve the self-care behaviors of the patients. Further-
more, the participants could access the mobile system and communicate with providers
without the limitations of time and place. Since most patients are also employed, they may
find it burdensome to receive education through hospital visits, owing to time and place
constraints. However, this study has several limitations that should be noted. First, we
did not evaluate the satisfaction of the patients with the app. User satisfaction needs to be
surveyed in the main study. Second, a bias may have occurred in the process of collecting
the cortisol. We did not closely monitor the participants; instead, we gave them instructions
for collecting cortisol by themselves. In addition, although the group assignment was
randomized, a performance bias could exist because the EG could guess that they were
receiving the intervention, and the intervention provider could also know to which group
the patients belonged. Therefore, the results should be interpreted with caution. Lastly,
this study is a pilot study conducted with a small sample size. While chronic hepatitis B is
usually a disease that requires lifelong treatment and follow-up, our study was conducted
over a short period of time and the long-term effectiveness of the intervention cannot
be determined. Therefore, larger samples and longer-term follow-up studies should be
conducted to further evaluate the effectiveness of this program.
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5. Conclusions
The findings of this pilot test indicate that the Hep B Care® program is a feasible
intervention for self-care for South Korean patients with chronic HBV. This mobile health
self-care program may be effective for improving self-care in this population because it can
provide tailored intervention based on the patients’ care needs. In addition, mobile health
intervention is known to be effective for improving self-care in middle-aged populations
familiar with receiving and exchanging information, including health information, via
smartphones. Finally, the results of this pilot study indicate that the Hep B Care® program
is feasible for improving the patients’ knowledge of the HBV and reducing their anxiety
levels.
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